190 related articles for article (PubMed ID: 37280314)
1. The loss of function GBA1 c.231C > G mutation associated with Parkinson disease.
Chen D; Zheng Y; Zhang G; Huang Y; Zheng B; Zhang J; Xiong F; Su Q
J Neural Transm (Vienna); 2023 Jul; 130(7):905-913. PubMed ID: 37280314
[TBL] [Abstract][Full Text] [Related]
2. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.
Menozzi E; Toffoli M; Schapira AHV
Pharmacol Ther; 2023 Jun; 246():108419. PubMed ID: 37080432
[TBL] [Abstract][Full Text] [Related]
3. Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation.
Yang SY; Gegg M; Chau D; Schapira A
Neurobiol Dis; 2020 Feb; 134():104620. PubMed ID: 31634558
[TBL] [Abstract][Full Text] [Related]
4. Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model.
Yang SY; Taanman JW; Gegg M; Schapira AHV
Hum Mol Genet; 2022 Jul; 31(14):2396-2405. PubMed ID: 35179198
[TBL] [Abstract][Full Text] [Related]
5. The relationship between glucocerebrosidase mutations and Parkinson disease.
Migdalska-Richards A; Schapira AH
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
[TBL] [Abstract][Full Text] [Related]
6. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
Ambrosi G; Ghezzi C; Zangaglia R; Levandis G; Pacchetti C; Blandini F
Neurobiol Dis; 2015 Oct; 82():235-242. PubMed ID: 26094596
[TBL] [Abstract][Full Text] [Related]
7. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.
Kumar M; Srikanth MP; Deleidi M; Hallett PJ; Isacson O; Feldman RA
Hum Mol Genet; 2023 May; 32(11):1888-1900. PubMed ID: 36752535
[TBL] [Abstract][Full Text] [Related]
8. Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease.
Ortega RA; Torres PA; Swan M; Nichols W; Boschung S; Raymond D; Barrett MJ; Johannes BA; Severt L; Shanker V; Hunt AL; Bressman S; Pastores GM; Saunders-Pullman R
J Clin Neurosci; 2016 Jun; 28():185-6. PubMed ID: 26857292
[TBL] [Abstract][Full Text] [Related]
9. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
Johnson PH; Weinreb NJ; Cloyd JC; Tuite PJ; Kartha RV
Mol Genet Metab; 2020 Feb; 129(2):35-46. PubMed ID: 31761523
[TBL] [Abstract][Full Text] [Related]
10. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
[TBL] [Abstract][Full Text] [Related]
11. A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers.
Yang SY; Beavan M; Chau KY; Taanman JW; Schapira AHV
Stem Cell Reports; 2017 Mar; 8(3):728-742. PubMed ID: 28216145
[TBL] [Abstract][Full Text] [Related]
12. A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease.
Burbulla LF; Jeon S; Zheng J; Song P; Silverman RB; Krainc D
Sci Transl Med; 2019 Oct; 11(514):. PubMed ID: 31619543
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients.
Parnetti L; Paciotti S; Eusebi P; Dardis A; Zampieri S; Chiasserini D; Tasegian A; Tambasco N; Bembi B; Calabresi P; Beccari T
Mov Disord; 2017 Oct; 32(10):1423-1431. PubMed ID: 28843015
[TBL] [Abstract][Full Text] [Related]
14.
Granek Z; Barczuk J; Siwecka N; Rozpędek-Kamińska W; Kucharska E; Majsterek I
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768367
[TBL] [Abstract][Full Text] [Related]
15. Can GBA1-Associated Parkinson Disease Be Modeled in the Mouse?
Farfel-Becker T; Do J; Tayebi N; Sidransky E
Trends Neurosci; 2019 Sep; 42(9):631-643. PubMed ID: 31288942
[TBL] [Abstract][Full Text] [Related]
16. D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model.
Kim D; Hwang H; Choi S; Kwon SH; Lee S; Park JH; Kim S; Ko HS
Acta Neuropathol Commun; 2018 Apr; 6(1):32. PubMed ID: 29703245
[TBL] [Abstract][Full Text] [Related]
17. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
[TBL] [Abstract][Full Text] [Related]
18. N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease.
García-Sanz P; Orgaz L; Bueno-Gil G; Espadas I; Rodríguez-Traver E; Kulisevsky J; Gutierrez A; Dávila JC; González-Polo RA; Fuentes JM; Mir P; Vicario C; Moratalla R
Mov Disord; 2017 Oct; 32(10):1409-1422. PubMed ID: 28779532
[TBL] [Abstract][Full Text] [Related]
19. Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function.
Kim MJ; Jeon S; Burbulla LF; Krainc D
Hum Mol Genet; 2018 Jun; 27(11):1972-1988. PubMed ID: 29579237
[TBL] [Abstract][Full Text] [Related]
20. The biochemical basis of interactions between Glucocerebrosidase and alpha-synuclein in GBA1 mutation carriers.
Toffoli M; Smith L; Schapira AHV
J Neurochem; 2020 Jul; 154(1):11-24. PubMed ID: 31965564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]